Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 25 May 2021
ICER publishes protocol for first annual assessment of drug coverage policies that present barriers to fair access
25 May 2021 - ICER’s analysis, based on MMIT’s market access analytics solution, will evaluate how 15 of the largest ...
Posted by Michael Wonder on 25 May 2021
AbbVie receives European Commission approval of Venclyxto (venetoclax) in combination with a hypomethylating agent for patients with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy
25 May 2021 - Venclyxto (venetoclax) in combination with a hypomethylating agent is a new regimen approved by the European ...
Posted by Michael Wonder on 25 May 2021
TG Therapeutics announces FDA acceptance of biologics license application for ublituximab in combination with Ukoniq (umbralisib) as a treatment for patients with chronic lymphocytic leukaemia and small lymphocytic lymphoma
25 May 2021 - Prescription Drug User Fee Act goal date of 25 March 2022. ...
Posted by Michael Wonder on 25 May 2021
Dupixent (dupilumab) now publicly reimbursed in Ontario and New Brunswick for the treatment of moderate to severe atopic dermatitis
25 May 2021 - Dupixent is the only biologic medicine approved by Health Canada to treat moderate to severe atopic dermatitis. ...
Posted by Michael Wonder on 25 May 2021
Merck receives positive EU CHMP opinion for Keytruda (pembrolizumab) in combination with chemotherapy as first-line treatment for certain patients with oesophageal cancer or HER2 negative gastro-oesophageal junction adenocarcinoma
24 May 2021 - Recommendation based on significant survival benefit demonstrated with Keytruda plus chemotherapy versus chemotherapy in Phase 3 KEYNOTE-590 ...
Posted by Michael Wonder on 25 May 2021
Scholar Rock receives fast track designation from the U.S. FDA for apitegromab for the treatment of patients with spinal muscular atrophy
24 May 2021 - Builds on Priority Medicines (PRIME) designation recently granted by the EMA recognising the unmet medical needs of ...
Posted by Michael Wonder on 25 May 2021
Verastem Oncology receives breakthrough therapy designation for VS-6766 with defactinib in recurrent low grade serous ovarian cancer
24 May 2021 - Results of early trial demonstrate 70% overall response rate in patients with KRAS mutant tumours, 44% ...
Posted by Michael Wonder on 25 May 2021
European Medicines Agency grants BioMarin's request for accelerated assessment of valoctocogene roxaparvovec for treatment of severe haemophilia A
24 May 2021 - MAA resubmission on track for June 2021. ...
Posted by Michael Wonder on 25 May 2021
European Commission approves Ponvory (ponesimod) for the treatment of adults with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features
25 May 2021 - Idorsia was informed by the Janssen that the European Commission has approved Ponvory (ponesimod) for the treatment ...
Posted by Michael Wonder on 25 May 2021
TGA approves more flexible storage conditions for Pfizer-BioNTech COVID-19 vaccine
24 May 2021 - Today, the TGA approved an application from Pfizer to change its current storage conditions for its ...
Posted by Michael Wonder on 24 May 2021
Why is Tagrisso not reimbursable as first-line treatment in Korea?
24 May 2021 - Osimertinib (Tagrisso) has transformed the treatment paradigm for epidermal growth factor receptor mutation positive non-small cell ...
Posted by Michael Wonder on 24 May 2021
Swiss pharma industry fights lower drug prices in the US
24 May 2021 - A proposed law currently under discussion in the United States Congress aims to lower prescription drug prices. ...
Posted by Michael Wonder on 24 May 2021
PHARMAC publishes record from Feb 2021 PTAC meeting
24 May 2021 - Yet another underwhelming meeting. ...
Posted by Michael Wonder on 24 May 2021
Akeso's penpulimab monoclonal antibody submitted BLA in the United States
24 May 2021 - First Chinese PD-1 drug being BLA reviewed by the FDA under real-time oncology review. ...
Posted by Michael Wonder on 24 May 2021
Boehringer Ingelheim's investigational treatment for cognitive impairment associated with schizophrenia receives FDA breakthrough therapy designation
24 May 2021 - BI 425809, a novel glycine transporter-1 (GlyT1) inhibitor to be studied in first of its kind Phase ...